Nicotinamide mononucleotide (NMN) supplements have gained attention for their potential to boost levels of nicotinamide adenine dinucleotide (NAD+), a coenzyme that declines with age and is linked to cellular health. However, as of June 2026, the scientific evidence for NMN's anti-aging effects in humans remains limited, with most studies conducted in animals or small human trials.
Research published in journals such as Nature Communications and Cell Metabolism has shown that NMN supplementation can increase NAD+ levels in humans. For example, a 2023 study in Nature Communications found that NMN improved muscle function in older adults, but the sample size was small (30 participants) and the effects were modest.
Regulatory status varies: In the United States, NMN is sold as a dietary supplement, but the FDA has raised concerns about its classification. In Japan, NMN is not approved as a drug but is available as a supplement. The European Food Safety Authority has not approved health claims for NMN.
Experts caution against overhyping NMN. Dr. David Sinclair, a prominent aging researcher at Harvard, has advocated for NAD+ boosters but acknowledges that long-term human data are lacking. The National Institute on Aging states that no supplement has been proven to slow or reverse aging in humans.
Consumers should consult healthcare providers before taking NMN, as potential side effects include nausea, fatigue, and headaches. Ongoing clinical trials are exploring NMN's effects on metabolic health, cardiovascular function, and cognitive decline.
